Retinal Physician – Gene Therapy Implications for Retina Specialists
[ad_1]
Just published, “Gene Therapy Implications for Retina Specialists: Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.”
The approval and launch of Spark’s LUXTURNA (voretigene neparvovec-ryzl), the first FDA-approved gene therapy for a genetic disease, introduces novel paradigms to clinical practice, including unfamiliar functional vision endpoints, new orphan disease treatment pathways, precision medicine, and genetic testing requirements.
Retinal Physician – Gene Therapy Implications for Retina Specialists
Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.
[ad_2]
Return to main website.